CHARTA Shows Survival Benefit of Four-Drug Regimen for Advanced CRC

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.

The CHARTA trial tested FOLFOX plus bevacizumab with or without irinotecan in patients with metastatic colorectal cancer.

In this video, Hans-Joachim Schmoll, MD, PhD, of the Martin Luther University Halle-Wittenberg in Halle, Germany, discusses results of the trial, covering the survival outcomes, subgroup analyses, and quality-of-life data.

The results of CHARTA (abstract 658) were presented at the 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held January 19–21 in San Francisco.

Recent Videos
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Related Content
The safety profile of lenvatinib/pembrolizumab plus TACE among patients with unresectable HCC was consistent with previously reported studies.

Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC

Roman Fabbricatore
October 30th 2025
Article

The safety profile of lenvatinib/pembrolizumab plus TACE among patients with unresectable HCC was consistent with previously reported studies.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Ariana Pelosci
October 29th 2025
Article

Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite stable mCRC.

Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer

Tim Cortese
October 27th 2025
Article

The anti–CTLA-4 antibody combination achieved an ORR of 34.8%, with 8 partial responses, in patients with pretreated microsatellite-stable mCRC.

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

FDA Grants BTD to Zenocutuzumab in NRG1+ Cholangiocarcinoma

Ariana Pelosci
October 24th 2025
Article

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.